Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HANK Immunotherapy in Metastatic NSCLC
NCT03007875Phase 2Completed
- Sponsor
- Fuda Cancer Hospital
- Start
- Dec 2016
- Primary completion
- Dec 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of high-activity natural killer cell therapy in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Fuda Cancer Hospital. Primary endpoint: Relief degree of tumors at 3 months. Started Dec 2016; status: completed.
02
Drugs
high-activity natural killer cell therapy
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03007875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03007875.